Protagonist Therapeutics (PTGX) Work In Process (2021 - 2024)

Protagonist Therapeutics has reported Work In Process for 4 years, with the latest figure at $165.0 million in Q4 2024.

• Quarterly Work In Process rose 1550.0% year-over-year to $165.0 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $165.0 million (up 1550.0% YoY) and the FY2024 annual result came in at $165.0 million, up 1550.0% from the prior year.
• Work In Process advanced to $165.0 million in Q4 2024 per PTGX's latest filing, from $43000.0 in the prior quarter.
• Over five years, Work In Process peaked at $300.0 million in Q1 2024 and troughed at $10000.0 in Q4 2022.
• A 4-year average of $68.1 million and a median of $1.6 million in 2021 frame the typical range for Work In Process.
• The sharpest annual moves came in 2022 and 2023: Work In Process slumped 99.36% in 2022, then surged 99900.0% in 2023.
• Over 4 years, Work In Process stood at $1.6 million in 2021, then plunged by 99.36% to $10000.0 in 2022, then soared by 99900.0% to $10.0 million in 2023, then surged by 1550.0% to $165.0 million in 2024.
• According to Business Quant data, Work In Process over the past three periods registered $165.0 million, $43000.0, and $300.0 million for Q4 2024, Q2 2024, and Q1 2024 respectively.